Caredx announces second quarter 2025 financial results

Brisbane, calif.--(business wire)--caredx, inc. (nasdaq: cdna) — the transplant company - a leading precision medicine company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today reported financial results for the second quarter ended june 30, 2025. second quarter 2025 financial highlights reported revenue of $86.7 million including a $3.8 million write-off of aged receivables ass.
CDNA Ratings Summary
CDNA Quant Ranking